Phase II trial of prednimustine, L-1031, (NSC-134087) in advanced breast cancer.

Abstract

The therapeutic effect of prednimustine was studied in 35 patients with advanced breast cancer resistant to previous cytotoxic and/or endocrine therapy. Response (PR + CR) was obtained in 14 patients (40%) of a median duration of five months. Among the 14 responding patients, 10 were resistant to previous endocrine therapy and chemotherapy, in all cases including alkylating agents, and 4 were resistant to previous endocrine therapy. Hematologic toxicity was rather pronounced, but other toxicities were only moderate.

• Authors: H T Mouridsen, D Kristensen, J H Nielsen, P Dombernowsky
• Journal: Cancer (Cancer) Vol. 46 Issue 2 Pg. 253-5 (Jul 15 1980) ISSN: 0008-543X [Print] United States
• PMID: 7388770 (Publication Type: Journal Article)

Chemical References

• Chlorambucil
• Prednimustine

Topics

• Adult
• Aged
• Breast Neoplasms (drug therapy)
• Chlorambucil (analogs & derivatives)
• Drug Evaluation
• Female
• Humans
• Leukopenia (chemically induced)
• Middle Aged
• Nausea (chemically induced)
• Prednimustine (adverse effects, therapeutic use)
• Psychoses, Substance-Induced (etiology)
• Thrombocytopenia (chemically induced)
• Time Factors
• Vomiting (chemically induced)